Bioinformatics analysis combined with experimental validation reveals the biological role of the ILK gene in prostate cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Integrin-linked kinase (ILK) drives prostate cancer (PCa) by influencing C-MYC. Inhibiting ILK shows promise for PCa treatment, reducing proliferation and increasing apoptosis.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Prostate cancer (PCa) is a common malignancy.
- Integrin-linked kinase (ILK) is an identified oncogenic driver in hormonal cancers, including PCa.
Purpose Of The Study
- To identify key genes in PCa.
- To investigate the role of ILK in PCa development and progression.
Main Methods
- Differential gene expression analysis and Weighted Gene Co-expression Network Analysis (WGCNA) were used.
- ILK gene silencing via siRNA was performed to assess impacts on cell proliferation, apoptosis, and cell cycle.
- Expression of autophagy and cell cycle proteins, alongside Mfuzz clustering, GSEA, immune function, TF, and drug prediction analyses were conducted.
Main Results
- WGCNA identified 544 significant genes; MYC emerged as a central regulatory gene.
- ILK silencing significantly inhibited LNCaP cell proliferation (P < 0.001) and increased apoptosis.
- ILK silencing led to S-phase cell cycle arrest and decreased C-MYC expression.
Conclusions
- ILK acts as an oncogene in PCa, primarily by influencing C-MYC.
- ILK inhibition presents a potential therapeutic strategy for managing PCa development and progression.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
